The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Azilsartan Medoxomil API Market Research Report 2025
Synopsis
Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.
The global Azilsartan Medoxomil API market was valued at US$ 15 million in 2023 and is anticipated to reach US$ 56 million by 2030, witnessing a CAGR of 20.0% during the forecast period 2024-2030.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
This report aims to provide a comprehensive presentation of the global market for Azilsartan Medoxomil API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Azilsartan Medoxomil API.
Report Scope
The Azilsartan Medoxomil API market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Azilsartan Medoxomil API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Azilsartan Medoxomil API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
Segment by Application
20 mg Tablets
40 mg Tablets
80 mg Tablets
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Azilsartan Medoxomil API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Azilsartan Medoxomil API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase.
The global Azilsartan Medoxomil API market was valued at US$ 15 million in 2023 and is anticipated to reach US$ 56 million by 2030, witnessing a CAGR of 20.0% during the forecast period 2024-2030.
Main manufacturers of global azilsartan medoxomil API market are Takeda, Metrochem API and Jubilant Pharma. Takeda and Metrochem API are the top 2 players and accounts for over 40% of global market share in total. Geographically speaking, USA is the largest market and covers about 30% of total market share, followed by Europe with 20%. In terms of application, 40 mg Tablets holds an important market share of over 50%.
This report aims to provide a comprehensive presentation of the global market for Azilsartan Medoxomil API, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Azilsartan Medoxomil API.
Report Scope
The Azilsartan Medoxomil API market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Azilsartan Medoxomil API market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Azilsartan Medoxomil API manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Takeda
Lupin
Acura Labs
Metrochem API
Jubilant Pharma
Zhejiang Hongyuan
Honour Lab
HEC Pharm
Enomark
CTX Life Sciences
Zhejiang Tianyu
Zhuhai Rundu
Valiant Co
Segment by Type
0.99
Others
Segment by Application
20 mg Tablets
40 mg Tablets
80 mg Tablets
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Azilsartan Medoxomil API manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Azilsartan Medoxomil API in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Azilsartan Medoxomil API Market Overview
1.1 Product Overview and Scope of Azilsartan Medoxomil API
1.2 Azilsartan Medoxomil API Segment by Type
1.2.1 Global Azilsartan Medoxomil API Market Value Comparison by Type (2024-2030)
1.2.2 0.99
1.2.3 Others
1.3 Azilsartan Medoxomil API Segment by Application
1.3.1 Global Azilsartan Medoxomil API Market Value by Application: (2024-2030)
1.3.2 20 mg Tablets
1.3.3 40 mg Tablets
1.3.4 80 mg Tablets
1.4 Global Azilsartan Medoxomil API Market Size Estimates and Forecasts
1.4.1 Global Azilsartan Medoxomil API Revenue 2019-2030
1.4.2 Global Azilsartan Medoxomil API Sales 2019-2030
1.4.3 Global Azilsartan Medoxomil API Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Azilsartan Medoxomil API Market Competition by Manufacturers
2.1 Global Azilsartan Medoxomil API Sales Market Share by Manufacturers (2019-2024)
2.2 Global Azilsartan Medoxomil API Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Azilsartan Medoxomil API Average Price by Manufacturers (2019-2024)
2.4 Global Azilsartan Medoxomil API Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Azilsartan Medoxomil API, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Azilsartan Medoxomil API, Product Type & Application
2.7 Azilsartan Medoxomil API Market Competitive Situation and Trends
2.7.1 Azilsartan Medoxomil API Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Azilsartan Medoxomil API Players Market Share by Revenue
2.7.3 Global Azilsartan Medoxomil API Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Azilsartan Medoxomil API Retrospective Market Scenario by Region
3.1 Global Azilsartan Medoxomil API Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Azilsartan Medoxomil API Global Azilsartan Medoxomil API Sales by Region: 2019-2030
3.2.1 Global Azilsartan Medoxomil API Sales by Region: 2019-2024
3.2.2 Global Azilsartan Medoxomil API Sales by Region: 2025-2030
3.3 Global Azilsartan Medoxomil API Global Azilsartan Medoxomil API Revenue by Region: 2019-2030
3.3.1 Global Azilsartan Medoxomil API Revenue by Region: 2019-2024
3.3.2 Global Azilsartan Medoxomil API Revenue by Region: 2025-2030
3.4 North America Azilsartan Medoxomil API Market Facts & Figures by Country
3.4.1 North America Azilsartan Medoxomil API Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Azilsartan Medoxomil API Sales by Country (2019-2030)
3.4.3 North America Azilsartan Medoxomil API Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Azilsartan Medoxomil API Market Facts & Figures by Country
3.5.1 Europe Azilsartan Medoxomil API Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Azilsartan Medoxomil API Sales by Country (2019-2030)
3.5.3 Europe Azilsartan Medoxomil API Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Azilsartan Medoxomil API Market Facts & Figures by Country
3.6.1 Asia Pacific Azilsartan Medoxomil API Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Azilsartan Medoxomil API Sales by Country (2019-2030)
3.6.3 Asia Pacific Azilsartan Medoxomil API Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Azilsartan Medoxomil API Market Facts & Figures by Country
3.7.1 Latin America Azilsartan Medoxomil API Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Azilsartan Medoxomil API Sales by Country (2019-2030)
3.7.3 Latin America Azilsartan Medoxomil API Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Azilsartan Medoxomil API Market Facts & Figures by Country
3.8.1 Middle East and Africa Azilsartan Medoxomil API Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Azilsartan Medoxomil API Sales by Country (2019-2030)
3.8.3 Middle East and Africa Azilsartan Medoxomil API Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Azilsartan Medoxomil API Sales by Type (2019-2030)
4.1.1 Global Azilsartan Medoxomil API Sales by Type (2019-2024)
4.1.2 Global Azilsartan Medoxomil API Sales by Type (2025-2030)
4.1.3 Global Azilsartan Medoxomil API Sales Market Share by Type (2019-2030)
4.2 Global Azilsartan Medoxomil API Revenue by Type (2019-2030)
4.2.1 Global Azilsartan Medoxomil API Revenue by Type (2019-2024)
4.2.2 Global Azilsartan Medoxomil API Revenue by Type (2025-2030)
4.2.3 Global Azilsartan Medoxomil API Revenue Market Share by Type (2019-2030)
4.3 Global Azilsartan Medoxomil API Price by Type (2019-2030)
5 Segment by Application
5.1 Global Azilsartan Medoxomil API Sales by Application (2019-2030)
5.1.1 Global Azilsartan Medoxomil API Sales by Application (2019-2024)
5.1.2 Global Azilsartan Medoxomil API Sales by Application (2025-2030)
5.1.3 Global Azilsartan Medoxomil API Sales Market Share by Application (2019-2030)
5.2 Global Azilsartan Medoxomil API Revenue by Application (2019-2030)
5.2.1 Global Azilsartan Medoxomil API Revenue by Application (2019-2024)
5.2.2 Global Azilsartan Medoxomil API Revenue by Application (2025-2030)
5.2.3 Global Azilsartan Medoxomil API Revenue Market Share by Application (2019-2030)
5.3 Global Azilsartan Medoxomil API Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Takeda
6.1.1 Takeda Corporation Information
6.1.2 Takeda Description and Business Overview
6.1.3 Takeda Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Takeda Azilsartan Medoxomil API Product Portfolio
6.1.5 Takeda Recent Developments/Updates
6.2 Lupin
6.2.1 Lupin Corporation Information
6.2.2 Lupin Description and Business Overview
6.2.3 Lupin Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Lupin Azilsartan Medoxomil API Product Portfolio
6.2.5 Lupin Recent Developments/Updates
6.3 Acura Labs
6.3.1 Acura Labs Corporation Information
6.3.2 Acura Labs Description and Business Overview
6.3.3 Acura Labs Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Acura Labs Azilsartan Medoxomil API Product Portfolio
6.3.5 Acura Labs Recent Developments/Updates
6.4 Metrochem API
6.4.1 Metrochem API Corporation Information
6.4.2 Metrochem API Description and Business Overview
6.4.3 Metrochem API Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Metrochem API Azilsartan Medoxomil API Product Portfolio
6.4.5 Metrochem API Recent Developments/Updates
6.5 Jubilant Pharma
6.5.1 Jubilant Pharma Corporation Information
6.5.2 Jubilant Pharma Description and Business Overview
6.5.3 Jubilant Pharma Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Jubilant Pharma Azilsartan Medoxomil API Product Portfolio
6.5.5 Jubilant Pharma Recent Developments/Updates
6.6 Zhejiang Hongyuan
6.6.1 Zhejiang Hongyuan Corporation Information
6.6.2 Zhejiang Hongyuan Description and Business Overview
6.6.3 Zhejiang Hongyuan Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Zhejiang Hongyuan Azilsartan Medoxomil API Product Portfolio
6.6.5 Zhejiang Hongyuan Recent Developments/Updates
6.7 Honour Lab
6.6.1 Honour Lab Corporation Information
6.6.2 Honour Lab Description and Business Overview
6.6.3 Honour Lab Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Honour Lab Azilsartan Medoxomil API Product Portfolio
6.7.5 Honour Lab Recent Developments/Updates
6.8 HEC Pharm
6.8.1 HEC Pharm Corporation Information
6.8.2 HEC Pharm Description and Business Overview
6.8.3 HEC Pharm Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.8.4 HEC Pharm Azilsartan Medoxomil API Product Portfolio
6.8.5 HEC Pharm Recent Developments/Updates
6.9 Enomark
6.9.1 Enomark Corporation Information
6.9.2 Enomark Description and Business Overview
6.9.3 Enomark Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Enomark Azilsartan Medoxomil API Product Portfolio
6.9.5 Enomark Recent Developments/Updates
6.10 CTX Life Sciences
6.10.1 CTX Life Sciences Corporation Information
6.10.2 CTX Life Sciences Description and Business Overview
6.10.3 CTX Life Sciences Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.10.4 CTX Life Sciences Azilsartan Medoxomil API Product Portfolio
6.10.5 CTX Life Sciences Recent Developments/Updates
6.11 Zhejiang Tianyu
6.11.1 Zhejiang Tianyu Corporation Information
6.11.2 Zhejiang Tianyu Azilsartan Medoxomil API Description and Business Overview
6.11.3 Zhejiang Tianyu Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Zhejiang Tianyu Azilsartan Medoxomil API Product Portfolio
6.11.5 Zhejiang Tianyu Recent Developments/Updates
6.12 Zhuhai Rundu
6.12.1 Zhuhai Rundu Corporation Information
6.12.2 Zhuhai Rundu Azilsartan Medoxomil API Description and Business Overview
6.12.3 Zhuhai Rundu Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Zhuhai Rundu Azilsartan Medoxomil API Product Portfolio
6.12.5 Zhuhai Rundu Recent Developments/Updates
6.13 Valiant Co
6.13.1 Valiant Co Corporation Information
6.13.2 Valiant Co Azilsartan Medoxomil API Description and Business Overview
6.13.3 Valiant Co Azilsartan Medoxomil API Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Valiant Co Azilsartan Medoxomil API Product Portfolio
6.13.5 Valiant Co Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Azilsartan Medoxomil API Industry Chain Analysis
7.2 Azilsartan Medoxomil API Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Azilsartan Medoxomil API Production Mode & Process
7.4 Azilsartan Medoxomil API Sales and Marketing
7.4.1 Azilsartan Medoxomil API Sales Channels
7.4.2 Azilsartan Medoxomil API Distributors
7.5 Azilsartan Medoxomil API Customers
8 Azilsartan Medoxomil API Market Dynamics
8.1 Azilsartan Medoxomil API Industry Trends
8.2 Azilsartan Medoxomil API Market Drivers
8.3 Azilsartan Medoxomil API Market Challenges
8.4 Azilsartan Medoxomil API Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
